Amplifybio
Advances translational science, cell and gene therapies and next-generation medicines for the benefit of millions of people around the world.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | $50.0m | Late VC | |
| Total Funding | 000k | ||
Related Content
AmplifyBio is a preclinical Contract Research Organization (CRO) and R&D outsourcing partner that specializes in the development and manufacturing of next-generation therapies. These therapies include cell, gene, mRNA, and other advanced modalities. The company operates in the biotechnology and pharmaceutical market, serving clients who are in the process of developing new therapeutic treatments.
AmplifyBio's business model is based on offering outsourced R&D solutions for benchmarking next-generation therapeutics. This includes discovery, optimization, and characterization services. Additionally, they offer safety, efficacy, and toxicology services, providing a comprehensive preclinical CRO solution built on a foundation of expertise and experience.
The company has recently expanded its services to include a Manufacturing Enablement Center. This new business unit offers manufacturing partnerships for multiple modalities, with flexible contract staffing models to meet varied client requirements.
AmplifyBio generates revenue through these contract services, charging clients for the research, development, and manufacturing services they provide. The company has received positive feedback from clients for its collaborative approach, expertise, and efficiency.
Keywords: Preclinical CRO, R&D Outsourcing, Next-Generation Therapies, Cell Therapy, Gene Therapy, mRNA Therapy, Discovery, Optimization, Characterization, Manufacturing Enablement.